Nelson Van Denburg & Campbell Wealth Management Group LLC Reduces Position in Entegris Inc (NASDAQ:ENTG)

Share on StockTwits

Nelson Van Denburg & Campbell Wealth Management Group LLC lessened its holdings in shares of Entegris Inc (NASDAQ:ENTG) by 18.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,960 shares of the semiconductor company’s stock after selling 1,360 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Entegris were worth $280,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Great West Life Assurance Co. Can raised its stake in shares of Entegris by 11.7% during the first quarter. Great West Life Assurance Co. Can now owns 19,638 shares of the semiconductor company’s stock valued at $698,000 after acquiring an additional 2,055 shares in the last quarter. Swiss National Bank raised its stake in shares of Entegris by 2.9% during the first quarter. Swiss National Bank now owns 257,600 shares of the semiconductor company’s stock valued at $9,194,000 after acquiring an additional 7,200 shares in the last quarter. GYL Financial Synergies LLC bought a new stake in shares of Entegris during the first quarter valued at approximately $1,102,000. Westfield Capital Management Co. LP bought a new stake in shares of Entegris during the first quarter valued at approximately $26,724,000. Finally, Marshall Wace LLP bought a new stake in shares of Entegris during the first quarter valued at approximately $9,842,000.

ENTG has been the subject of several research analyst reports. ValuEngine downgraded shares of Entegris from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. CL King initiated coverage on shares of Entegris in a research note on Thursday, June 20th. They set a “buy” rating and a $44.00 price target for the company. Zacks Investment Research raised shares of Entegris from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research note on Tuesday. Deutsche Bank downgraded shares of Entegris from a “buy” rating to a “hold” rating in a research note on Sunday, October 6th. They noted that the move was a valuation call. Finally, Citigroup set a $45.00 price objective on shares of Entegris and gave the stock a “hold” rating in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Entegris has a consensus rating of “Buy” and an average target price of $46.29.

Shares of NASDAQ:ENTG opened at $46.23 on Friday. The company has a market capitalization of $6.16 billion, a price-to-earnings ratio of 24.46 and a beta of 1.36. Entegris Inc has a 52 week low of $23.39 and a 52 week high of $48.43. The company has a quick ratio of 3.66, a current ratio of 4.87 and a debt-to-equity ratio of 0.85. The firm has a 50 day moving average of $45.28 and a 200 day moving average of $40.12.

Entegris (NASDAQ:ENTG) last issued its quarterly earnings data on Thursday, July 25th. The semiconductor company reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.04). The business had revenue of $378.90 million during the quarter, compared to the consensus estimate of $382.02 million. Entegris had a return on equity of 24.13% and a net margin of 18.18%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. On average, sell-side analysts expect that Entegris Inc will post 1.91 EPS for the current year.

In other news, SVP William James Shaner sold 24,294 shares of the company’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $44.33, for a total transaction of $1,076,953.02. Following the transaction, the senior vice president now directly owns 25,536 shares of the company’s stock, valued at $1,132,010.88. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Gregory B. Graves sold 25,974 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $45.00, for a total value of $1,168,830.00. Following the transaction, the chief financial officer now directly owns 74,521 shares in the company, valued at $3,353,445. The disclosure for this sale can be found here. Insiders sold 72,812 shares of company stock valued at $3,242,453 in the last three months. 1.50% of the stock is currently owned by insiders.

Entegris Company Profile

Entegris, Inc develops, manufactures, and supplies micro contamination control products, specialty chemicals, and advanced materials handling solutions for manufacturing processes in the semiconductor and other high-technology industries worldwide. It operates through three segments: Specialty Chemicals and Engineered Materials (SCEM); Microcontamination Control (MC); and Advanced Materials Handling (AMH).

Further Reading: What is the Fibonacci sequence?

Want to see what other hedge funds are holding ENTG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entegris Inc (NASDAQ:ENTG).

Institutional Ownership by Quarter for Entegris (NASDAQ:ENTG)

Receive News & Ratings for Entegris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entegris and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$164.56 Million in Sales Expected for EPR Properties  This Quarter
$164.56 Million in Sales Expected for EPR Properties This Quarter
WXCOINS  Reaches 1-Day Trading Volume of $13.00
WXCOINS Reaches 1-Day Trading Volume of $13.00
nDEX  Reaches 1-Day Trading Volume of $1,204.00
nDEX Reaches 1-Day Trading Volume of $1,204.00
HC Wainwright Reaffirms Hold Rating for Trillium Therapeutics
HC Wainwright Reaffirms Hold Rating for Trillium Therapeutics
Cyclacel Pharmaceuticals  Raised to “Strong-Buy” at Zacks Investment Research
Cyclacel Pharmaceuticals Raised to “Strong-Buy” at Zacks Investment Research
Fulcrum Therapeutics  Lifted to Hold at Zacks Investment Research
Fulcrum Therapeutics Lifted to Hold at Zacks Investment Research


© 2006-2019 Ticker Report